FrançaisAre analysts right about Catalyst Pharmaceuticals Partners, Inc. (CPRX)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Catalyst Pharmaceuticals Partners, Inc., we replayed every analyst price target of the past 12 months and measured the real outcome: 0% were profitable, average return +0% (56 calls). At 3 months: +0% average return (0% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| HC Wainwright & Co. | 14 | 0% | +0% |
| Cantor Fitzgerald | 9 | 0% | +0% |
| Truist Securities | 8 | 0% | +0% |
Frequently asked questions
Is Catalyst Pharmaceuticals Partners, Inc. a buy right now?
The analyst consensus on Catalyst Pharmaceuticals Partners, Inc. (CPRX) is "Hold" (2 bullish, 0 bearish calls over 12 months). This is not advice: historically, 0% of their targets on this stock turned out profitable over 1 year.
What is Catalyst Pharmaceuticals Partners, Inc.'s price target?
The median 12-month price target is $31.50 (+0% vs $31.49), ranging from $31.50 to $31.50 (2 analysts).
Are analysts accurate on Catalyst Pharmaceuticals Partners, Inc.?
Over 1 year, 0% of analyst targets on Catalyst Pharmaceuticals Partners, Inc. were profitable, for an average return of +0% (across 56 timestamped calls). This is JPI Invest's accuracy metric.
What is the Catalyst Pharmaceuticals Partners, Inc. stock forecast?
Analysts target a median of $31.50 within 12 months, i.e. +0% vs the current price. The most bullish targets $31.50, the most cautious $31.50.
What is the Catalyst Pharmaceuticals Partners, Inc. stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $31.50, +0%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (0%), and the stock's past trajectory.
Is Catalyst Pharmaceuticals Partners, Inc. overvalued?
Detailed valuation data for Catalyst Pharmaceuticals Partners, Inc. is available in the interactive analysis.
📊 See the full interactive analysis of Catalyst Pharmaceuticals Partners, Inc. →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.